We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Gains from Focus on Coronavirus Treatments
Read MoreHide Full Article
Shares of biotech major Regeneron Pharmaceuticals (REGN - Free Report) have gained 16.4% against the industry’s decline of 6.3%.
Price has rallied particularly in the past few days as Regeneron is one of the few biotech companies along with Gilead Sciences, Inc. (GILD - Free Report) , Moderna Inc. (MRNA - Free Report) and GlaxoSmithKline Plc (GSK - Free Report) that is working on drugs and vaccines for the treatment coronavirus, as more and more cases are being reported every day.
Reportedly, President Trump has asked these companies to speed up their efforts for this cause.
Last month, Regeneron expanded its agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, which has been declared a global public health emergency by the World Health Organization.
The HHS and Regeneron Other Transaction Agreement (OTA) focuses on the discovery, research, development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose a significant risk to public health, now including the Influenza virus and 2019-nCoV.
Regeneron’s fourth-quarter results were impressive, wherein both sales and earnings beat estimates on the label expansion of Eylea and strong Dupixent sales in moderate-to-severe atopic dermatitis and asthma. Libtayo is off to a strong start as well. The company’s efforts to expand the label of its approved drugs and concurrently develop its pipeline are encouraging.
The FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent, seeking approval for the treatment of children aged 6 to 11 years with moderate-to-severe atopic dermatitis, with a target action date of May 26, 2020.
A phase II neoadjuvant study in cutaneous squamous cell carcinoma (CSCC) was initiated as well.
The immuno-oncology platform with a wide portfolio of bispecific antibodies is progressing well too.
The company is also making collaborations to strengthen its pipeline. Regeneron entered into a research collaboration and option licensing agreement with Vyriad, Inc. to discover and develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer.
Importantly, Regeneron’s collaboration with BARDA to address the novel coronavirus is encouraging and a possible outcome should further boost performance.
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Regeneron (REGN) Gains from Focus on Coronavirus Treatments
Shares of biotech major Regeneron Pharmaceuticals (REGN - Free Report) have gained 16.4% against the industry’s decline of 6.3%.
Price has rallied particularly in the past few days as Regeneron is one of the few biotech companies along with Gilead Sciences, Inc. (GILD - Free Report) , Moderna Inc. (MRNA - Free Report) and GlaxoSmithKline Plc (GSK - Free Report) that is working on drugs and vaccines for the treatment coronavirus, as more and more cases are being reported every day.
Reportedly, President Trump has asked these companies to speed up their efforts for this cause.
Last month, Regeneron expanded its agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, which has been declared a global public health emergency by the World Health Organization.
The HHS and Regeneron Other Transaction Agreement (OTA) focuses on the discovery, research, development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose a significant risk to public health, now including the Influenza virus and 2019-nCoV.
Regeneron’s fourth-quarter results were impressive, wherein both sales and earnings beat estimates on the label expansion of Eylea and strong Dupixent sales in moderate-to-severe atopic dermatitis and asthma. Libtayo is off to a strong start as well. The company’s efforts to expand the label of its approved drugs and concurrently develop its pipeline are encouraging.
The FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent, seeking approval for the treatment of children aged 6 to 11 years with moderate-to-severe atopic dermatitis, with a target action date of May 26, 2020.
A phase II neoadjuvant study in cutaneous squamous cell carcinoma (CSCC) was initiated as well.
The immuno-oncology platform with a wide portfolio of bispecific antibodies is progressing well too.
The company is also making collaborations to strengthen its pipeline. Regeneron entered into a research collaboration and option licensing agreement with Vyriad, Inc. to discover and develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer.
Importantly, Regeneron’s collaboration with BARDA to address the novel coronavirus is encouraging and a possible outcome should further boost performance.
Regeneron currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>